Vivoryon Therapeutics N.V. to Hold its Annual General Meeting on June 22, 2022

Halle (Saale) / Munich, Germany, May 11, 2022 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon; or the Company), a clinical stage company focused on discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that its Annual General Meeting will be held on Wednesday, June 22, 2022, at 1:00 p.m. (CEST). Shareholders can follow the AGM virtually via audio webcast on the Company’s website (https://www.vivoryon.com/ordinary-general-meeting-of-shareholders-2022/), or attend in person at Novotel Amsterdam City, Europaboulevard 10, 1083 AD Amsterdam, The Netherlands.

The full agenda and all relevant documents are available on the Company’s website.

The agenda includes, among other items, the re-appointment of Vivoryon’s Non-Executive Board members. In line with the Company’s commitment to meet international best practice standards, Vivoryon proposes to appoint two additional Non-Executive Directors to its Board of Directors. Consequently, the agenda includes, among other topics, the following voting items:

• Appointment of Dr. Claudia Riedl as Non-Executive Director to Vivoryon’s Board of Directors:

Dr. Riedl (formerly Gutjahr-Löser) is a seasoned investor relations and communications professional in the biotechnology industry and brings senior executive, corporate communications, and investor relations expertise to Vivoryon. Dr. Riedl’s broad expertise also includes senior advisory roles in a number of IPOs and financings in various geographies. During her more than 15‑year tenure as Head of Corporate Communications and Investor Relations at the German biotech MorphoSys until 2016, she supported the company’s transformation and growth from a technology-focused antibody discovery and development enterprise into a fully integrated biopharmaceutical company. Subsequently, in a senior advisor capacity, she was instrumental in the company’s successful secondary listing on Nasdaq in 2018. Following an apprenticeship at Deutsche Bank AG, Dr. Riedl studied biology and earned a PhD at Technical University, Munich, Germany.

• Appointment of Samir Shah, MD, as Non-Executive Director to Vivoryon’s Board of Directors:

Dr. Shah is a seasoned expert in the pharmaceutical industry. In addition to his current role as Head of Investor Relations for Novartis, a company he has been with since 2004, he is a member of several executive groups and committees within the organization, including Finance Leadership Team, Innovation Management Board and Trust & Reputation Committee. Beyond investor relations, his broad expertise includes the senior executive, business development, commercial and financial sectors. Prior to Novartis, Dr. Shah spent more than 12 years at Merck Serono, where he led several global franchises, including neurology. He graduated as a physician from University of Sheffield, England and joined the pharmaceutical industry after completing his postgraduate medical training (MRCP). Dr. Shah also holds an MBA from the University of Warwick, England.

###

About Vivoryon Therapeutics N.V.

Vivoryon is a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Beyond our lead program, varoglutamstat, which is in Phase 2 clinical development to treat Alzheimer‘s disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis. www.vivoryon.com

Vivoryon Forward Looking Statements

This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of the Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.

For more information, please contact:

Investor Contact

Vivoryon Therapeutics N.V.

Dr. Manuela Bader, Director IR & Communication

Tel: +49 (0)345 555 99 30

Email:

Media Contact

Trophic Communications

Valeria Fisher

Tel: +49 175 8041816

Email: